¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀÎALL¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-04-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀÎALL¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-04-20
±³À°ÀÏÀÚ : 2024-04-20
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾çAI¼¾Å¸ AIȦ

±³À°ÁÖÁ¦ : 2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀÎALL¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼ºÀÎALL¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀÎ : 70¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í ºñȸ¿ø 50,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 10:00~10:30 "CAR T cell therapy in adult ALL(acute lymphoblastic leukemia) " ¹éµ¿ÈÆ(°æºÏÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 10:30~11:00 "ASH guidelines for adolescents and young adults ALL (acute lymphoblastic leukemia) " ±èµµ¿µ(ºÎ»êÀÇ)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 11:10~11:40 Recent diagnostic advances in adults ALL(acute lymphoblastic leukemia) ÀÌÁ¾¹Ì(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 11:40~12:10 Recent therapeutic advances in adults ALL(acute lymphoblastic leukemia) ÀÌÁ¾Çõ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 13:10~13:50 Advances in gene-engineered immune cells of cancer therapy ÀÌÇý¼±(KAIST)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 13:50~14:30 Global trends of CAR T cell therapy in cancer Á¶¼öÈñ(CuroCell)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 14:50~15:05 Updated clinical outcomes & predictive factors to blinatumomab in patients with relapsed/refractory BCP-ALL ¹éµ¿¿ø(°æºÏÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 15:05~15:20 Phase II trial of Rituximab preconditioning for relapsed/refractory B-cell ALL treated with blinatumomab (RICOBAL) º¯ÀÚ¹Î(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 15:20~15:30 A phase 2 clinical trial to evaluate the efficacy of Venetoclax and Decitabine in relapsed/refractory adult T acute lymphoblastic leukemia/lymphoma (VEDETTE Study) ½Åµ¿¿±(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 15:30~15:40 Post-transplant therapy with hypomethylating agent in Philadelphia chromosome negative adult acute lymphoblastic leukemia ¹éµ¿¿ø(°æºÏÀÇ´ë)

±³À°½Ã°£ 04¿ù 20ÀÏ AIȦ 15:40~15:50 "Ponatinib based induction therapy followed by allogeneic stem cell transplantation with pre-emptive use of ponatinib for patients with Philadelphia positive B-cell acute lymphoblastic leukemia, prospective, multicenter study " ¹éµ¿¿ø(°æºÏÀÇ´ë )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 ´ëÇÑÇ÷¾×ÇÐȸ ¼ºÀÎALL¿¬±¸È¸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-04-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÇ÷°ü¿Ü°úÇÐȸ16th Vascular Ultrasound Seoul Update 2023 Symposium (1ÀÏÂ÷) : 2024-04-20
´ÙÀ½±Û (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (4¿ù) : 2024-04-20 [1]
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20500 ¼­¿ï 2024 Á¦2Â÷ ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸºÎÀοµ»ó¿¬±¸ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-12 0 12 2024-04-29
20499 ¼­¿ï Çѱ¹Á¤½ÅÄ¡·áÇÐȸ Á¤½ÅÄ¡·á Áõ·Ê¹ßÇ¥ : 2024-05-11 0 11 2024-04-29
20498 ºÎ»ê ¸¸¼ºÆó¼â °ü»óµ¿¸Æ ÁßÀç½Ã¼ú¿¬±¸È¸ The 23rd K-CTO(Korean Chronic Total Occlusion Club) Live Demonstration : 2024-05-11 0 29 2024-04-29
20497 ¼­¿ï ´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11 0 22 2024-04-29
20496 ¼­¿ï 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-11 0 18 2024-04-29
20495 ¼­¿ï Á¦77Â÷ ´ëÇÑû°¢ÇÐȸ Çмú´ëȸ : 2024-05-11 0 27 2024-04-29
20494 ÀÎõ Á¦9ȸ °¡Ãµ´ë ±æº´¿ø ½Å°æ¿Ü°ú ¾÷µ¥ÀÌÆ® ½ÉÆ÷Áö¿ò (G-NeUS) : 2024-05-11 0 13 2024-04-29
20493 ´ëÀü 2024³â ´ëÇѽŰæÁßÀçÄ¡·áÀÇÇÐȸ Ãá°èÇмú´ëȸ & Basic Training Course : 2024-05-11 0 9 2024-04-29
20492 ±¤ÁÖ 2024³â ´ëÇѼҾƺñ´¢ÀÇÇÐȸ Á¦37Â÷ Çмú´ëȸDAY2 : 2024-05-11 0 11 2024-04-29
20491 ¼­¿ï Á¦50ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2024-05-11 0 21 2024-04-29
20490 ¼­¿ï ÇѾç´ëÇб³º´¿ø Á¤Çü¿Ü°ú ⸳ 52Áֳ⠱â³äÇмú´ëȸ : 2024-05-11 0 44 2024-04-29
20489 ¼­¿ï °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ¼ºÇü¿Ü°úÇб³½Ç â¸³ 50Áֳ⠱â³ä Çмú´ëȸ : 2024-05-11 0 15 2024-04-29
20488 °æ±â ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2024 Spring Semi-Annual Meeting (2ÀÏÂ÷) : 2024-05-11 0 21 2024-04-29
20487 °­¿ø 2024³â ´ëÇѺ´¸®ÇÐȸ º½Çмú´ëȸ(2ÀÏÂ÷) : 2024-05-10 0 18 2024-04-29
20486 ¼­¿ï 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-10 0 24 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷